GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Photocure A PHO.OL · NOK

Health Care · Oslo Børs · 🇳🇴 Norway

Compare

42.10

-5.61%

Close of 9 Nov 2026, in NOK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Photocure A

Its shares trade on Oslo Børs under the ticker PHO.OL. It has been listed since 29 May 2000. In the fiscal year to 31 December 2025, it reported revenue of NOK 532.6m and a net loss of NOK 1.5m. At that date it held total assets of NOK 707.1m and shareholders' equity of NOK 484.2m.

Photocure ASA is a pharmaceutical company, which engages in the provision of photodynamic diagnosis and treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 May 2000
Employees
67

Leadership

Pay as last reported

  • Mr. Dylan HallerbergInterim Chairman of the Board, since 2023
  • Mr. Daniel SchneiderPresident, Chief Executive Officer
  • Mr. Erik DahlChief Financial OfficerNOK 1.7m
  • Ms. Jane HealyVice President, General Manager, EMEA
  • Ms. Susanne StraussVice President, General Manager - Europe
  • Mrs. Grete HogstadVice President Global Strategic Marketing and BDNOK 1.7m
  • Ms. Patricia KellyVice President Global Human Resources
  • Mr. Geoffrey CoyVice President, General Manager - US Operations
  • Mr. Anders NeijberChief Medical Officer, Global Medical Affairs and Clinical Development and R&D
  • Ms. Malene BrondbergDirector
  • Dr. Neal ShoreDirector
  • Dr. Johanna HolldackIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.